Conference Call with Caplin Point Laboratories Management and Analysts on Q1FY27 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Caplin Point Laboratories announced Q1FY27 results Consolidated Financial Highlights: Revenue from operations: The company reported revenue from operations of Rs 610.36 crore in Q1FY27, an increase of 19.63% YoY from Rs 510.22 crore in Q1FY26 and a growth of 1.70% QoQ from Rs 600.16 crore in Q4FY26. Total Revenue: Total revenue stood at Rs 643.91 crore in Q1FY27, up 20.73% YoY compared to Rs 533.36 crore in Q1FY26 and up 2.45% QoQ compared to Rs 628.52 crore in Q4FY26. EBITDA: EBITDA reached Rs 247.03 crore in Q1FY27, reflecting a growth of 22.96% YoY from Rs 200.90 crore in Q1FY26 and 6.20% QoQ from Rs 232.60 crore in Q4FY26. Profit Before Tax (PBT): The company recorded a PBT of Rs 225.22 crore in Q1FY27, up 22.10% YoY from Rs 184.46 crore in Q1FY26 and a 5.52% QoQ increase from Rs 213.44 crore in Q4FY26. Net Profit after Tax (PAT): Net profit for Q1FY27 was Rs 179.09 crore, showing an 18.79% YoY increase from Rs 150.76 crore in Q1FY26 and a 3.59% QoQ growth from Rs 172.88 crore in Q4FY26. Earnings Per Share (EPS): Basic EPS for Q1FY27 was Rs 23.27, an increase from Rs 20.10 in Q1FY26. Standalone Financial Highlights: Revenue from operations: Standalone revenue for Q1FY27 was Rs 202.95 crore, up 11.16% YoY from Rs 182.57 crore in Q1FY26 and up 6.06% QoQ from Rs 191.36 crore in Q4FY26. Total Income: Total standalone income stood at Rs 265.74 crore in Q1FY27, a 23.83% YoY increase from Rs 214.60 crore in Q1FY26. Net Profit: The standalone net profit for the quarter was Rs 120.38 crore in Q1FY27, compared to Rs 85.89 crore in Q1FY26 (up 40.16% YoY) and Rs 120.81 crore in Q4FY26 (marginal decline of 0.36% QoQ). Business Highlights: Segment Performance: Rest of the World (Emerging Markets): This segment recorded revenue of Rs 476.07 crore in Q1FY27 compared to Rs 403.53 crore in Q1FY26. The segment results (PBT) were Rs 158.40 crore in Q1FY27. USA: Revenue from the US market reached Rs 134.29 crore in Q1FY27, up from Rs 106.69 crore in Q1FY26. The segment results (PBT) showed a significant jump to Rs 33.27 crore in Q1FY27 from Rs 9.86 crore in Q1FY26. Emerging Markets Update: The company won emergency tenders across Central America amounting to USD 7 million to be supplied over the next two quarters. In Chile, tenders to the tune of USD 12 million were won for supply over the next 18 months. Mexico Operations: Caplin received four additional product approvals in Mexico and plans to file for another 120+ products in the next 18 months. Caplin Steriles Limited (CSL): The subsidiary currently has 60 ANDAs approved and 5 under review. CSL has launched 38 products in the US to date and plans 12 more launches in FY27. Strategic Growth Initiatives: Caplin Point has allocated an enhanced Capex budget of approximately Rs 1,000 + crore for investment projects, with around 50% nearing completion. These projects include an Oncology API facility (Target Q4FY27) and an OSD and COL Injectable facility (Target Q1FY28). Dividends: The Board recommended a Final Dividend of Rs 4/- (200%) per equity share of Rs 2/- each for FY26. An interim dividend of Rs 4/- was already paid in June 2026. Cash Position: As of June 30, 2026, free cash reserves stood at Rs 1,502 crore with total liquid assets at Rs 2,875 crore. C.C. Paarthipan, Chairman, said: We are pleased to begin FY27 on a strong and encouraging note, with the Company delivering healthy growth across both our Emerging Markets and the US, while continuing to strengthen the foundations for sustainable long-term growth. Our Q1 performance reflects the consistency of our strategy, the resilience of our business model and the disciplined execution across our expanding portfolio and geographies. The continued momentum in Latin America, the accelerating contribution from the US, and the progress across our manufacturing, R&D; and backward-integration initiatives reinforce our confidence in the opportunities ahead. At the same time, our strong balance sheet and substantial liquidity provide us with the flexibility to continue investing in capacity, capabilities and new markets. As we move forward, our focus remains firmly on building a more integrated, diversified and future-ready pharmaceutical platform, while creating enduring value for all our stakeholders. Result PDF
Conference Call with Caplin Point Laboratories Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Caplin Point Laboratories announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations for Q4FY26 stood at Rs 600.16 crore, representing a YoY increase of 19.4% compared to Rs 502.45 crore in Q4FY25 and a QoQ growth of 10.6% from Rs 542.77 crore in Q3FY26. Total Income for the quarter was Rs 628.52 crore, reflecting a YoY growth of 19.0% as against Rs 528.19 crore and a 9.0% increase QoQ from Rs 576.45 crore. Profit Before Tax (PBT) for Q4FY26 reached Rs 213.44 crore, up 20.8% YoY from Rs 176.67 crore and up 4.7% QoQ from Rs 203.89 crore in Q3FY26. Net Profit for the quarter (PAT) stood at Rs 172.88 crore, marking a 19.0% increase YoY compared to Rs 145.28 crore and a 4.2% increase QoQ from Rs 165.86 crore. For the full year ended March 31, 2026, Revenue from Operations was Rs 2,187.19 crore, a growth of 12.9% YoY from Rs 1,937.47 crore in FY25. Annual Total Income for FY26 was Rs 2,302.73 crore, showing a 13.2% increase over Rs 2,033.90 crore in FY25. Annual Net Profit (PAT) for FY26 stood at Rs 649.73 crore, registering a 20.1% growth from Rs 541.09 crore in FY25. Earnings Per Share (EPS) for Q4FY26 was Rs 22.38 (Basic), compared to Rs 18.75 in Q4FY25. For FY26, Basic EPS reached Rs 84.36, up from Rs 70.57 in FY25. Standalone Financial Highlights: Revenue from Operations for Q4FY26 was Rs 191.36 crore, reflecting a 10.2% YoY growth from Rs 173.61 crore in Q4FY25 and a 1.1% QoQ increase from Rs 189.22 crore in Q3FY26. Total Income for the quarter reached Rs 252.44 crore, compared to Rs 214.86 crore in Q4FY25 and Rs 220.95 crore in Q3FY26. Profit Before Tax (PBT) for Q4FY26 stood at Rs 137.72 crore, a 25.0% increase YoY as against Rs 110.16 crore and a 17.7% increase QoQ from Rs 117.01 crore. Net Profit (PAT) for the quarter was Rs 109.50 crore, up 26.6% YoY from Rs 86.50 crore and up 25.5% QoQ from Rs 87.28 crore. For FY26, Standalone Revenue from Operations was Rs 738.33 crore, compared to Rs 752.41 crore in FY25. Annual Standalone Net Profit (PAT) for FY26 was Rs 396.58 crore, representing a 16.8% increase YoY from Rs 339.49 crore. Business Highlights: Geographical Segment Performance: Rest of the World: This segment recorded a revenue of Rs 470.25 crore in Q4FY26 and Rs 1,733.79 crore For FY26. Segment results (PBT) for the year reached Rs 631.20 crore. USA: This segment generated a revenue of Rs 129.91 crore in Q4FY26 and Rs 453.40 crore For FY26. Segment results (PBT) for the year stood at Rs 56.05 crore. Interim Dividend: The Board of Directors declared an Interim Dividend of Rs 4.00 (200%) per equity share of face value Rs 2 each for the financial year ended March 31, 2026. Caplin Steriles USA Inc (CSU) Performance: CSU completed its first full year of operations with approximately USD 11 million in revenue and 26.2% EBITDA, achieving profitability and self-sustaining cash flow within its first year. CSU has launched 30 products to date with plans to launch 15 more in the current year. Product Approvals and Pipeline: The company received 10 ANDA approvals in FY26 and acquired 15 ANDAs from third parties, bringing the total ANDA tally to 59, an increase of 25 ANDAs over FY25. In Mexico, the company received approvals for 25 products with a pipeline of over 120 products to be filed within 18 months. Capacity Expansion: The company is expanding its IV Bag line capacity to 3X its current size. Construction of the COL-II facility is expected to be completed by December 2026, which will house 5 Injectable, Ophthalmic, and BFS lines. Strategic Growth and Capex: Caplin Point has allocated an enhanced Capex budget of approximately Rs 1,000 + crore for investment projects, with about 50% nearing completion. Latin America Update: The company entered the Brand Marketing CNS segment in three Latin American markets, with plans to expand to two more in 2027. Labour Code Impact: The company assessed the implications of the New Labour Codes, resulting in an increase in employee benefit obligations (gratuity and compensated absences) aggregating to Rs 1.39 crore (Consolidated) and Rs 0.84 crore (Standalone). C.C. Paarthipan, Chairman, said: The financial year FY26 has been another year of steady progress and disciplined execution for the Company. We have delivered strong financial performance, with sustained margins, healthy cash generation, and consistent growth across our key markets. The strength of our unique end-to-end business model is showcased clearly by the consistency of these numbers, at a larger base also. Our Emerging Markets business continues to be a reliable growth engine, driven by deep market presence, expanding product portfolios, and increasing participation in institutional channels. At the same time, we are making meaningful strides in strengthening our footprint in Regulated Markets, particularly in the United States, where Caplin Steriles is gaining scale and depth. During the year, we made significant investments in building future capabilities — across manufacturing, automation, compliance strengthening, backward integration, product development, and regulatory filings. Our progress in Oncology, APIs, and complex dosage forms such as Pre-Filled Syringes and BlowFill-Seal technology, positions us well for the next phase of growth. Importantly, these investments are being made while maintaining strong cash flows and a robust balance sheet. We remain debt-free and will continue to remain so. We are also encouraged by the early success of Caplin Steriles USA, our front-end initiative in the US, which achieved profitability within its first year of operations — an outcome that reflects both execution discipline and the strength of our product selection. This was done without a de-growth in our B2B business, which shows our discipline in capacity utilization and ensuring consistent supply across segments. As we look ahead, our focus remains clear: to build a diversified and resilient business across geographies, deepen our presence in complex and differentiated products, and continue investing in quality, compliance, and automation. Initiatives such as our backward integration program, expansion into new technologies, and digital transformation efforts will play a critical role in strengthening our competitive position. While we remain optimistic about the opportunities ahead, we will continue to approach growth with prudence and discipline, staying aligned with our core principles of sustainable and profitable expansion. I would like to thank our employees for their dedication, our partners for their continued trust, and our shareholders for their unwavering support. Result PDF
Pharmaceuticals company Caplin Point Laboratories announced Q3FY26 results Revenue: Rs 542.8 crore against Rs 493 crore during Q3FY25, change 10%. EBITDA: Rs 223.4 crore against Rs 193.7 crore during Q3FY25, change 15%. EBITDA Margin: 38.7% for Q3FY26. PBT: Rs 203.9 crore against Rs 177.3 crore during Q3FY25, change 15%. PBT Margin: 35.4% for Q3FY26. PAT: Rs 165.9 crore against Rs 140.1 crore during Q3FY25, change 18%. PAT Margin: 28.8% for Q3FY26. C.C. Paarthipan, Chairman, said: Our performance in Q3FY26 and 9MFY26 reflects far more than financial outcomes - it reflects the quiet compounding of a long-term strategy built on being different from others. We have sustained our strong margins, expanded profitability, and delivered robust cash generation, all while continuing to invest heavily in capacity, technology, people and future platforms. This balance between growth and prudence remains central to how we think about building enduring value. In Emerging Markets, our end-to-end business model continues to create a powerful competitive moat, as we create enriching value on both sides by catering to the bottom of the pyramid. By keeping products closer to customers, expanding local presence, and broadening our portfolio through internal development and global partnerships, we are steadily deepening relevance in markets that value reliability, affordability, and long-term commitment. Our progress in Latin America, the scaling of GLP-1 products, the acceleration of our “China 2.0” strategy, and our investments in oncology and APIs reinforce our belief that resilience is built through thoughtful vertical integration and geographic diversification. In the US and other regulated markets, Caplin Steriles continues to move up the complexity curve — combining strong compliance, first-cycle approvals, advanced drug-delivery platforms, and increasing automation. The early success of our US front end, along with investments in pre-filled syringes, BFS, and “Visual Integration” project positions us well for the next phase of growth. As we look ahead, we remain guided by a simple principle: build compliance through automation, expand capabilities ahead of demand, and grow businesses that can compound sustainably. With a strong balance sheet, a deep pipeline, and a clear strategic roadmap, we are confident in our ability to create lasting value for patients, partners, and shareholders alike. Result PDF